Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Interested to see Alistairs Ablynx comment again..... with today’s appointment? Plan coming together perhaps .
With the ‘unfortunate’ Covid opportunity worth potentially xbn., my guess they’ll be lining up...
GLA
xxxyyyzzz, great post.
We have so many things going on for avacta that I expect multiple rnss shortly. It is a waiting game for us.
Good luck mate.
I‘ve always wondered about this, I don‘t think Nasdaq = unicorn because of being a biotech. Always had TILS/TLSA Tiziana Life Sciences in mind ever since people were floating the AVCT dual listing musings. They are dual listed and aren‘t in the billions (especially not before COVID). Just a thought, it‘s not that easy. Let‘s not put the horse ahead of the cart. The patient will hopefully be rewarded, and I understand the wait is the hardest part and being filled with speculation on the boards. Keep holding on.
v
Yes I agree things are certainly looking positive here. Indeed, I have topped up twice today and will look to add further. This appointment is a real plus for AVCT. Moreover, we have our test coming on line very soon. I can see AVCT becoming a major player in due course.
Thank you for your knowledge shared here.
Just wanted to ask the board a little question
When do you think we could possibly join the NASDAQ and what will the SP be at minimum to join?
Thanks
xxxyyyzzz,
I take your point, but could we consider that the appointment of Neil Bell as Chief Development Officer implies also that AS would take onboard his views on possibly have a Nasdaq listing, or even a move out of AIM?
As being able to have their fingers on so many pies at the same time shows avacta is able to expand rapidly their projects.
ST
Add to that about a years wait whilst the US SEC carries out its due diligence so effectively any US Listing could be 3 years away. Suspect they’ll be taken out before then !
While Neil was at Autolus, he played a key role in their listing on NASDAQ.
This is VERY significant and can’t come soon enough for Avacta (a NASDAQ listing) so that it’s true value can be established far above what it is at present.
Interesting to see Neil was at Teva for a while - according to its website, Teva are “one of the top 5 global suppliers of oncology treatments on the WHO Essential Medicines List.”
I wonder what Always winning and Icemans view of this appointment is unless the heat took care of the Iceman. They were saying all sorts but this is a clear appointment AVCT is not messing about and glad they're using the placement money to throw the kitchen sink at the cancer side as well. The CEO is a genius how he managed to get that massive placement to secure AVCT future like that.
Just a joke. We know, Profit00. Pleased you have some acceptance
Michbeans, if Avacta succeeds in therapeutics and targeted cancer therapies then you can be sure the share price will be pinned to £50 (per share).
Excellent appointment and show great intent!
Cheers Rich
Neil won't come cheap.
I have no doubts AVCT are 100% convinced they will be generating the revenue to keep a man of this calibre pinned to his desk with ton bags stuffed with £50 notes.
Neil Bell helped Autolus onto NASDAQ just two years ago.
Great appointment - shows that Avacta is so much more than a Covid stock.
LONDON, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced changes to the company’s executive leadership team. Dr. Jim Faulkner, Senior Vice President, Head of Product Delivery; and Neil Bell, Senior Vice President, Head of Clinical Operations, will be departing Autolus.
“Jim and Neil have been valued members of Autolus’ leadership team. I want to thank them both for the significant contributions they’ve made to building our clinical pipeline and establishing our manufacturing base, which is now fully operational. The entire Autolus team wishes them well as they embark on their next endeavors.”
Neil Bell, Chief Development Officer of Avacta Life Sciences commented:
"I am delighted to join the therapeutics team at Avacta Life Sciences at such an exciting time in its growth trajectory and where I believe the Company has significant opportunity to build a successful and agile clinical stage biopharmaceutical organisation with the capability to maximise its early development oncology assets for the ultimate benefit of patients. I very much look forward to working closely with Alastair and the therapeutics senior leadership team to establish a leading position for Avacta Life Sciences as a focused immunotherapy oncology company."
At Autolus Neil was responsible for building a fully functional global clinical operations team delivering Phase I/II clinical studies across the UK, Europe and US in acute lymphoblastic leukemia, multiple myeloma, B-cell lymphoma, and T-cell lymphoma, and implemented the first commercially sponsored CAR-T study in the UK.